Volume 2, Issue 1 p. 47-51
Preliminary Communication

Antiparkinsonian activity of single oral dose of PHNO

F. Grandas

F. Grandas

University Department of Neurology, King's College Hospital Medical School and Institute of Psychiatry, London UK

Search for more papers by this author
N. Quinn

N. Quinn

University Department of Neurology, King's College Hospital Medical School and Institute of Psychiatry, London UK

Search for more papers by this author
P. Critchley

P. Critchley

University Department of Neurology, King's College Hospital Medical School and Institute of Psychiatry, London UK

Search for more papers by this author
A. Rohan

A. Rohan

University Department of Neurology, King's College Hospital Medical School and Institute of Psychiatry, London UK

Search for more papers by this author
Prof. C. D. Marsden

Corresponding Author

Prof. C. D. Marsden

University Department of Neurology, King's College Hospital Medical School and Institute of Psychiatry, London UK

Department of Neurology, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UKSearch for more papers by this author
S. M. Stahl

S. M. Stahl

University Department of Neurology, King's College Hospital Medical School and Institute of Psychiatry, London UK

Search for more papers by this author
First published: 1987
Citations: 10

Abstract

PHNO, a new D-2 agonist, was investigated in five patients with Parkinson's disease. In an acute, open, oral, dose-ranging study comparing benefit from single doses, 4 mg of PHNO was found to be equivalent to one tablet of Sinemet 25/250 mg. Adverse reactions were those anticipated for a dopaminomimetic agent. Because of its novel structure and apparent transcutaneous penetration, further studies on PHNO are desirable.